Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma

Prashant Mujumdar, Joanna Kopecka, Silvia Bua, Claudiu T. Supuran, Chiara Riganti, Sally‐Ann Poulsen

Journal of Medicinal Chemistry · 2019 · 34 citations · 24 references

DOIFull text

Open access

Concepts

Abstract

The natural product primary sulfonamide, psammaplin C (1), when used in combination with clinically used chemotherapeutic drugs, including temozolomide, reverses multidrug resistance and increases survival in glioblastoma, a highly aggressive primary brain tumor. We showed previously that the mechanism of action of 1 is novel, acting to indirectly interfere with P-glycoprotein drug efflux activity as a consequence of carbonic anhydrase XII (CA XII) inhibition. To build structure–activity relationships, 45 derivatives of 1 were designed, synthesized, and evaluated against a panel of CA isoforms. Compound 55 was identified as a potent inhibitor of CA XII (Ki = 0.56 nM) and was investigated in vitro and in vivo using samples from glioblastoma patients. The results strengthen the possibility that co-therapy of temozolomide with a CA XII inhibitor may more effectively treat glioblastoma by suppressing an important temozolomide resistance mechanism.

References

24